Page 2 - ஈவேற்ச் லீ மருத்துவ விநியோகி மேலாண்மை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஈவேற்ச் லீ மருத்துவ விநியோகி மேலாண்மை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஈவேற்ச் லீ மருத்துவ விநியோகி மேலாண்மை Today - Breaking & Trending Today

Molecular Partners and Novartis Announce Inclusion of COVID-19 Antiviral Candidate, ensovibep, in NIH-Sponsored ACTIV-3 Trial


Provided by
Accesswire
Mar 15, 2021 6:00 AM UTC
ACTIV-3 trial planned to investigate safety and efficacy of ensovibep in adults hospitalized with a COVID-19 diagnosis; first patient dose expected in Q2 2021
Ensovibep to be first non-antibody therapeutic assessed in ACTIV-3
Clinical trial includes an interim analysis after 300 patients
Separately, a global Phase 2-3 study in adults with mild to moderate symptoms is planned to be initiated in Q2 2021
Initial Phase 1 data support safety, tolerability and 2-3 week half-life of ensovibep
ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / March 15, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, and its collaborator Novartis, today announced that ensovibep (formerly MP0420) is expected to be included in a global phase 3 randomized, controlled clinical trial as part of the Na ....

Shai Biran , Seth Lewis , Thomas Schneckenburger , Patrick Amstutz , National Institutes Of Health , Drug Administration , Company On Twitter At Molecularprtnrs , Molecular Partners , National Institutes , Investigational New Drug , Molecular Partner , Ivers Lee Clinical Supply Management , Swiss Government , ஷாய் பிரன் , சேதி லெவிஸ் , பேட்ரிக் அம்சட்டுட்ஸ் , தேசிய நிறுவனங்கள் ஆஃப் ஆரோக்கியம் , மூலக்கூறு கூட்டாளர்கள் , தேசிய நிறுவனங்கள் , மூலக்கூறு கூட்டாளர் , ஈவேற்ச் லீ மருத்துவ விநியோகி மேலாண்மை , சுவிஸ் அரசு ,

Molecular Partners AG: Molecular Partners and Novartis Report Positive Initial Results from Phase 1 Study of its COVID-19 Antiviral Therapy, Ensovibep, in Healthy Volunteers


Molecular Partners AG: Molecular Partners and Novartis Report Positive Initial Results from Phase 1 Study of its COVID-19 Antiviral Therapy, Ensovibep, in Healthy Volunteers
Predictable exposure seen post administration, confirming the expected half-life of 2-3 weeks
Global phase 2/3 registrational study planned to initiate in Q2 2021
ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE /
March 9, 2021 / Molecular Partners AG (SWX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, and its collaborator Novartis, today announced initial results from its ongoing phase 1 study of its first tri-specific COVID-19 antiviral treatment, ensovibep (MP0420), in healthy volunteers.
In the placebo-controlled phase 1 study, healthy volunteers were randomized 3:1 to receive an infusion of ensovibep, or placebo, respectively. Two dosing cohorts have been fully enrolled and received a single infusion of ....

United Kingdom , Shai Biran , Nicolas Leupin , Seth Lewis , Thomas Schneckenburger , Company On Twitter At Molecularprtnrs , Molecular Partners , Molecular Partner , Ivers Lee Clinical Supply Management , Swiss Government , Co Vid , ஒன்றுபட்டது கிஂக்டம் , ஷாய் பிரன் , சேதி லெவிஸ் , மூலக்கூறு கூட்டாளர்கள் , மூலக்கூறு கூட்டாளர் , ஈவேற்ச் லீ மருத்துவ விநியோகி மேலாண்மை , சுவிஸ் அரசு , இணை வித் ,